Direct adsorption of low-density lipoprotein by DALI-LDL-apheresis: Results of a prospective long-term multicenter follow-up covering 12 291 sessions

Therapeutic Apheresis and Dialysis

Volumn 10, Issue 3, 2006, Pages 210-218

  Bosch, Thomas ^a   Gahr, Simon ^a   Belschner, Ulrike ^a   Schaefer, Claudia ^a   Lennertz, Andrea ^a   Rammo, Jörg ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b FRESENIUS MEDICAL CARE   (Germany)

Author keywords

DALI; DALI apheresis; LDL; LDL apheresis; LDL hemoperfusion; Lp(a)

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHENPROCOUMON;

ADOLESCENT; ADSORPTION; ADULT; AGED; APHERESIS; ARTICLE; ATHEROSCLEROSIS; CHILD; CLINICAL TRIAL; DIRECT ADSORPTION OF LIPOPROTEIN; FEMALE; FOLLOW UP; HEMOPERFUSION; HUMAN; HYPERCHOLESTEROLEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ATHEROSCLEROSIS; BLOOD COMPONENT REMOVAL; CHILD; FEMALE; FOLLOW-UP STUDIES; HEMOPERFUSION; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEIN(A); LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33745549429     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2006.00336.x     Document Type: Article

References (23)

1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of lowering cholesterol with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:1623-30.
2. Thompson GR. LDL apheresis. Atherosclerosis 2003;167:1-13.
3. Grundy SM, Cleeman JI, Merz CNB et al. The coordinating committee of the national cholesterol education program. Circulation 2004;110:227-39.
4. Thomas HP, Steinhagen-Thiessen E. Lipoprotein (a). Z Kardiol 2003;92(Suppl. 3):III/53-8.
5. Bosch T. Therapeutic apheresis: state of the art in the year 2005. Ther Apher Dial 2005;9:459-68.
6. Bosch T, Schmidt B, Kleophas W et al. LDL hemoperfusion - A new procedure for LDL apheresis: first clinical application of an LDL adsorber compatible with human whole blood. Artif Organs 1997;21:977-81.
7. Bosch T, Lennertz A, Schmidt B et al. DALI apheresis in hyperlipidemic patients. Biocompatibility, efficacy and selectivity of direct adsorption of lipoproteins from whole blood. Artif Organs 2000;24:81-90.
8. Wendler T, Lennertz A, Heinemann O, Duhr C, Samtleben W, Bosch T. Heparin-free DALI LDL-apheresis in hyperlipidemic patients: efficacy, safety and biocompatibility. Int J Artif Organs 2000;23:710-7.
9. Bosch T, Heinemann O, Duhr C et al. Effect of low-dose citrate anticoagulation on the clinical safety and efficacy of direct adsorption of lipoproteins (DALI apheresis) in hypercholesterolemic patients - a prospective controlled clinical trial. Artif Organs 2000;24:790-6.
10. Bosch T, Wendler T, Jaeger BR, Samtleben W. Improvement of hemorheology by DALI apheresis: acute effects on plasma viscosity and erythrocyte aggregation in hypercholesterolemic patients. Ther Apher 2001;5:372-6.
11. Bosch T, Keller C. Clinical effects of DALI-LDL-apheresis: beyond cholesterol reduction. Ther Apher Dial 2003;7:341-4.
12. Wendler T, Schilling R, Lennertz A et al. Efficacy and safety of DALI LDL-apheresis at high blood flow rates: a prospective multicenter study. J Clin Apher 2003;18:157-66.
13. Jansen M, Banyai S, Schmaldienst S et al. Direct adsorption of lipoproteins from whole blood, first long-term clinical experience with a new LDL-apheresis system for the treatment of familial hypercholesterolemia. Wien Klin Wochenschr 2000;112:61-9.
14. Dräger LJ, Julius U, Kränzle K et al. DALI-the first human whole-blood LDL and Lp(a) apheresis system in clinical use: procedure and clinical results. Eur J Clin Invest 1998;28:994-1002.
15. Bosch T, Lennertz A, Schenzle D, Dräger J for the DALI Study Group. Direct adsorption of low-density liporotein and lipoprotein (a) from whole blood: results of the first clinical long-term multicenter study using DALI apheresis. J Clin Apher 2002;17:161-9.
16. BUB-Richtlinien. Deutsches Ärzteblatt 2003;100:2035-6.
17. Otto C, Kern P, Bambauer R, Kallert S, Schwandt P, Parhofer KG. Efficacy and safety of a new whole-blood low-density lipoprotein apheresis system (liposorber D) in severe hypercholesterolemia. Artif Organs 2003;27:1116-22.
18. Richter W, Donner M, Höfling B, Schwandt P. Long-term effect of LDL apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Metabolism 1998;47:863-8.
19. Gordon BR, Kelsey SF, Dau PC et al. Long-term effects of LDL apheresis using an automated dextransulfate cellulose adsorption system. Am J Cardiol 1998;81:407-11.
20. Schuff-Werner P. Heparin-induzierte extrakorporale LDL-Präzipitation (HELP). In: Schwandt P, Richter WO, Parhofer KG, eds. Handbuch der Fettstoffwechselstörungen, 2nd edn. Stuttgart: Schattauer, 2001;538-56.
21. Koga N, Nagano T, Sato T, Kagasawa K. Anaphylactoid reactions and bradykinin generation in patients treated with LDL apheresis and an ACE inhibitor. ASAIO J 1993;39:M288-91.
22. Bosch T, Wendler T. Efficacy and safety of DALI-LDL-apheresis in two patients treated with the angiotensin II-receptor 1 - antagonist losartan. Ther Apher Dial 2004;8:269-74.
23. Schiel R, Bambauer R, Müller U. Low-density lipoprotein apheresis versus lipid lowering drugs in the treament of severe hypercholesterolemia: four years' experience. Artif Organs 1996;20:318-23.